Study: New blood thinner works as well as Coumadin

Nov 15, 2010 By MARILYNN MARCHIONE , AP Medical Writer

(AP) -- A study finds that a new and easier-to-use blood thinner prevents strokes in people with a common heart rhythm problem as well as Coumadin does, and without an increase in bleeding or side effects.

The drug is called rivaroxaban (riv-ah-ROCKS-ah-ban). It was tested against warfarin, the generic version of Coumadin, in more than 14,000 people with atrial . That's the most common heart rhythm problem in America. It occurs when the upper parts of the heart quiver instead of beating normally. This raises the risk of clots that can cause a .

Johnson & Johnson and Bayer Healthcare plan to seek federal approval to sell the drug later this year. Doctors gave results of the study Monday at a heart conference in Chicago.

Explore further: WHO says five more Ebola vaccines to be tested in March

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Study: Plavix plus aspirin helps prevent strokes

Mar 31, 2009

(AP) -- Taking the blood thinner Plavix along with aspirin helped prevent strokes and heart attacks in people with a common heartbeat abnormality that puts them at high risk of these problems, doctors reported Tuesday.

Blood-Thinning Drug Linked to Increased Bleeding in Brain

Sep 29, 2008

(PhysOrg.com) -- Patients who take the commonly used blood-thinning drug warfarin face larger amounts of bleeding in the brain and increased risk of mortality if they suffer a hemorrhagic stroke, new research from the University ...

Blood thinner causes stroke in some dialysis patients

Aug 27, 2009

The blood thinner warfarin can prevent strokes in most individuals with abnormal heart rhythms, but the drug may have the opposite effect in kidney disease patients on dialysis, according to a study appearing in an upcoming ...

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

23 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0